EYPT earnings / call / takeaways

EYPT Q3 FY26 earnings call: key takeaways

What EYPT said on its earnings call of November 12, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 12, 2026·AI-generated from the call transcript and Lician data

EYPT reported a loss of $0.88 per share, missing the consensus estimate of -$0.88
The company is refocusing its efforts on the DME program after Phase III wet AMD trials did not meet their primary endpoint. (13:09)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	-$0.88	–	–
Revenue	$233,080	–	–

EPS basis: Unverified: no SEC figure to check the provider EPS against

What changed since last quarter

The company has shifted focus to DME after discontinuing the WET-AMD program. (13:09)
Financial runway is expected to last into late Q3 2027, with $118 million in cash. (20:09)
The DME trials, Como and Capri, are expected to report top-line results in early Q4 2027. (18:29)

What analysts pressed on

Whether the DME trials will account for patient variability and protect non-inferiority margins. (23:24)
If there is a plan for futility analysis in the DME studies. (26:04)
How the age and comorbidities of DME patients compare to those in wet AMD and impact trial outcomes. (26:49)

In their words

We are deeply disappointed with this result. (13:09)
DuraVue has the potential to address both VEGF-driven vascular permeability and IL-6-driven inflammation with one therapy. (16:32)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.